Intensive Care Unit, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
J Investig Med. 2024 Aug;72(6):567-573. doi: 10.1177/10815589241249997. Epub 2024 May 15.
This systematic review and meta-analysis aimed to determine the efficacy of inhaled corticosteroids (ICS) on mortality in patients with coronavirus disease-2019 (COVID-19). A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on the treatment of COVID-19 with ICS were reviewed. Studies were pooled to risk ratios (RRs), with 95% confidence intervals (CIs). Eleven RCTs (enrolling 5832 participants) met the inclusion criteria. There was no statistically significant difference in COVID-19-related death (RR 0.88, 95% CI 0.38-2.04), all-cause death (RR 1.05, 95% CI 0.49-2.23), and invasive ventilation (RR 1.26, 95% CI 0.60-2.62) between the two groups. ICS was not associated with reduced mortality and invasive ventilation in patients with COVID-19.
本系统评价和荟萃分析旨在确定吸入性皮质类固醇（ICS）对 2019 年冠状病毒病（COVID-19）患者死亡率的疗效。系统检索了 PubMed、Embase、Cochrane 图书馆和 clinicaltrials.gov，无语言限制。纳入了使用 ICS 治疗 COVID-19 的随机对照试验（RCT）。将研究汇总为风险比（RR），置信区间（CI）为 95%。符合纳入标准的 RCT 有 11 项（纳入 5832 名参与者）。两组 COVID-19 相关死亡（RR 0.88，95% CI 0.38-2.04）、全因死亡（RR 1.05，95% CI 0.49-2.23）和有创通气（RR 1.26，95% CI 0.60-2.62）无统计学差异。ICS 并未降低 COVID-19 患者的死亡率和有创通气。
